Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4999121 | 0.80 | HTR3A (0.42) | HTR3AHRH4FLT3MAPK14MAPK8 | |
| SCHEMBL4990127 | 0.72 | HRH4 (0.46) | HTR3AHRH4 | |
| SCHEMBL4990139 | 0.72 | HRH4 (0.46) | HTR3AHRH4 | |
| SCHEMBL2580371 | 0.68 | HRH4 (0.60) | HTR3AHRH4MAPK8 | |
| SCHEMBL2580361 | 0.68 | HRH4 (0.60) | HTR3AHRH4MAPK8 | |
| SCHEMBL2580369 | 0.68 | HRH4 (0.60) | HTR3AHRH4MAPK8 | |
| SCHEMBL4999115 | 0.67 | HRH4 (0.46) | HTR3AHRH4 | |
| SCHEMBL4999125 | 0.67 | HRH4 (0.46) | HTR3AHRH4 | |
| SCHEMBL18550559 | 0.65 | HRH4 (0.56) | HTR3AHRH4 | |
| SCHEMBL18550560 | 0.65 | HRH4 (0.56) | HTR3AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | HRH4, HRH2, HRH3 | HTR3A 333/4885HRH4 1/4885UCHL1 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.